- Conditions
- Solid Tumor, Non-Small-Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer
- Interventions
- ASP5834, panitumumab
- Drug
- Lead sponsor
- Astellas Pharma Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 364 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 11
- States / cities
- Santa Monica, California • Atlanta, Georgia • Jefferson, Louisiana + 8 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 102
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Non Small-cell Lung Cancer, Locally Advanced Unresectable NSCLC, Locally Advanced Metastatic NSCLC
- Interventions
- AMG 510
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 99 Years
- U.S. locations
- 30
- States / cities
- Huntsville, Alabama • Anchorage, Alaska • Chandler, Arizona + 27 more
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Sotorasib, 960 mg, oral daily dose for 4 weeks (28 days)
- Drug
- Lead sponsor
- Fox Chase Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Locally Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
- Interventions
- Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Sotorasib, Trastuzumab Deruxtecan
- Procedure · Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 9
- States / cities
- Sacramento, California • Tampa, Florida • Wesley Chapel, Florida + 4 more
- Conditions
- Advanced Solid Tumor (Phase 1), Pancreas Adenocarcinoma, Non-small Cell Lung Cancer, Malignant Melanoma (Cutaneous)
- Interventions
- IMM-6-415
- Drug
- Lead sponsor
- Immuneering Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 5
- States / cities
- Scottsdale, Arizona • Duarte, California • Denver, Colorado + 2 more
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- VIC-1911, sotorasib
- Drug
- Lead sponsor
- Vitrac Therapeutics, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 5
- States / cities
- Sacramento, California • North Haven, Connecticut • Atlanta, Georgia + 2 more
- Conditions
- Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
- Interventions
- Biopsy, Biospecimen Collection, Carfilzomib, Computed Tomography, Echocardiography, Magnetic Resonance Imaging, Sotorasib
- Procedure · Drug
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 2
- States / cities
- Duarte, California • Irvine, California
- Conditions
- Advanced Non-squamous Non-small-cell Lung Cancer
- Interventions
- ERAS-007, ERAS-601, Osimertinib, Sotorasib
- Drug
- Lead sponsor
- Erasca, Inc.
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 11
- States / cities
- Duarte, California • Orange, California • Santa Monica, California + 7 more
- Conditions
- Lung Neoplasm Malignant
- Interventions
- MK-1084, Patritumab deruxtecan, Sacituzumab tirumotecan, Cetuximab, Rescue Medications
- Drug · Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 190 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 4
- States / cities
- Clermont, Florida • Chicago, Illinois • Portland, Oregon
- Conditions
- KRAS G12C Mutation, KRAS G12S Mutation, Solid Tumor Malignancies, CRC (Colorectal Cancer)
- Interventions
- KQB365, Cetuximab, KQB198
- Drug
- Lead sponsor
- Kumquat Biosciences Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 11
- States / cities
- Phoenix, Arizona • Denver, Colorado • Jacksonville, Florida + 8 more
- Conditions
- Solid Tumors
- Interventions
- Adagrasib, Pembrolizumab, Cetuximab, Pemetrexed, Docetaxel, Irinotecan, Leucovorin, Oxaliplatin, Fluorouracil
- Drug
- Lead sponsor
- Mirati Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 170 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 17
- States / cities
- Phoenix, Arizona • Bellflower, California • Long Beach, California + 13 more
- Conditions
- Non-Small Cell Lung Cancer (NSCLC)
- Interventions
- Sotorasib, Pembrolizumab
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 750 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2032
- U.S. locations
- 22
- States / cities
- Santa Barbara, California • Newark, Delaware • Chicago, Illinois + 17 more
- Conditions
- Metastatic Colorectal Cancer, KRAS G12C Mutations
- Interventions
- Cetuximab, Cemiplimab, Adagrasib
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • Houston, Texas
- Conditions
- Colon Adenocarcinoma, Rectal Adenocarcinoma
- Interventions
- Calderasib, Oxaliplatin, Leucovorin/levofolinate calcium, 5-Fluorouracil, Cetuximab, Bevacizumab, Bevacizumab biosimilar
- Drug · Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 477 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 31
- States / cities
- Los Angeles, California • Fort Collins, Colorado • Lone Tree, Colorado + 27 more
- Conditions
- KRAS p.G12C Mutant Advanced Solid Tumors
- Interventions
- sotorasib, Anti PD-1/L1, Midazolam
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 713 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 39
- States / cities
- Duarte, California • Los Angeles, California • San Francisco, California + 29 more
- Conditions
- Non-Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Solid Tumor
- Interventions
- Inlexisertib, Trametinib, Binimetinib, Sotorasib
- Drug
- Lead sponsor
- Deciphera Pharmaceuticals, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 91 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 10
- States / cities
- Boston, Massachusetts • St Louis, Missouri • New Brunswick, New Jersey + 7 more
- Conditions
- Advanced Cancer, Metastatic Cancer, Malignant Neoplasm of Lung
- Interventions
- Adagrasib
- Drug
- Lead sponsor
- Mirati Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 4
- States / cities
- Santa Rosa, California • Kansas City, Missouri • Durham, North Carolina + 1 more
- Conditions
- Advanced Colorectal Cancer, Metastatic Colorectal Cancer
- Interventions
- MRTX849, Cetuximab, mFOLFOX6 Regimen, FOLFIRI Regimen
- Drug · Biological
- Lead sponsor
- Mirati Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 461 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 185
- States / cities
- Alabaster, Alabama • Bessemer, Alabama • Birmingham, Alabama + 122 more
- Conditions
- Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
- Interventions
- Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Panitumumab, Sotorasib
- Procedure · Biological · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 180
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Los Angeles, California + 135 more
- Conditions
- Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer
- Interventions
- Divarasib, Sotorasib, Adagrasib
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 338 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 25
- States / cities
- Gilbert, Arizona • Los Angeles, California • San Francisco, California + 21 more
- Conditions
- Non Small Cell Lung Cancer, NSCLC, KRAS G12C
- Interventions
- Adagrasib, Stereotactic Radiosurgery
- Drug · Radiation
- Lead sponsor
- Ryan Gentzler, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 3
- States / cities
- Columbus, Ohio • Charlottesville, Virginia • Richmond, Virginia
- Conditions
- Lung Cancer
- Interventions
- AMG 510, Cisplatin, Carboplatin, Pemetrexed
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 2
- States / cities
- New York, New York • Houston, Texas
- Conditions
- Neoplasms, Advanced Solid Tumors, Non-small Cell Lung Cancer, Colorectal Cancer
- Interventions
- JNJ-74699157
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 4
- States / cities
- Sarasota, Florida • Tampa, Florida • Nashville, Tennessee + 1 more
- Conditions
- Solid Tumor, NSCLC
- Interventions
- JAB-3312, Binimetinib, Pembrolizumab, Sotorasib, Osimertinib
- Drug
- Lead sponsor
- Allist Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 15
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 12 more